subpath:

Cramer says Vertex has a drug that may address the ‘largest market opportunity in the world'

  • 📰 NBCNewYork
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 63%

United Kingdom News News

United Kingdom United Kingdom Latest News,United Kingdom United Kingdom Headlines

CNBC’s Jim Cramer said investors keep an eye on Vertex Pharmaceuticals (VRTX) as the company develops a non-opioid pain drug.

"The biggest pharmacy issue how do we get pain removed, or at least nullified, without opiates? They have a plan — Vertex," Cramer said onunderway for the pain drug, known as VX-548. Vertex has said its goal is to create a new class of prescription medications that relieve pain and address the shortcomings of opioids, namely their addictive potential.

"I do believe that if they have something, it would be the largest market opportunity in the world," Cramer said, adding that late-stage study results for VX-548 are expected"within the year."In a note to clients Monday, analysts at Leerink Partners argued that the investment community significantly underappreciates" the potential for VX-548.

San Francisco quarterback Brock Purdy makes nearly $1 million a year — but splits rent with a roommate and drives a Toyota SUV31-year-old teacher quit her job. Now she works at Costco—and boosted her income by 50%: ‘I've never been happier'

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 270. in UK
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United Kingdom United Kingdom Latest News, United Kingdom United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Jim Cramer's top 10 things to watch in the stock market MondayThe Dow, S&P 500 and Nasdaq were lower Monday after Hamas conducted a surprise attack on Israel.
Source: CNBC - 🏆 12. / 72 Read more »